Materials and methods

Bacterial isolates
The bacterial strains were 45 control strains positive or negative for ESBLs and 81 clinical isolates. Control strains, expressing plasmid-mediated ESBLs or other -lactamases, were kindly provided by George Jacoby (Lahey Hitchcock Clinic, Burlington, MA, USA), Ronald Jones (University of Iowa College of Medicine, Iowa City, IA, USA) and David Livermore (London Hospital Medical College, London, UK). The 14 enzymes expressed by the 27 ESBL-positive Escherichia coli (mostly J53 or c600 transconjugants) included two TEM-3, two TEM-4, one TEM-5, three TEM-6, two TEM-7, one each of TEM-8, -9, -10, -12, and -26, and three each of SHV-2, -3, -4 and -5. [4] [5] [6] [7] The 18 ESBL-negative control strains used were as follows: three E. coli strains expressing plasmid-mediated TEM-1 (two low-level producers and one hyperproducer), 8 two expressing TEM-2, four SHV-1 and one each of OXA-1, -4 and -7; one Klebsiella pneumoniae strain expressing OXA-3; E. coli J53-R -, E. coli c600-R -, E. coli JP995, 8 E. coli ATCC 35218 and E. coli ATCC 25922. The 81 clinical strains were nine non-duplicate E. coli and 72 K. pneumoniae isolates from hospitalized patients in Hong Kong. These clinical isolates were putative ESBL producers on the basis of a positive result in the double-disc synergy test. E. coli ATCC 25922, E. coli ATCC 35218 and Pseudomonas aeruginosa ATCC 27853 were used as controls.
Antimicrobial agents
Clavulanate was obtained from SmithKline Beecham, Hong Kong. Discs impregnated with individual antibiotics were obtained commercially (BBL, Becton Dickinson, Cockeysville, MD, USA). Etest ESBL screen (TZ/TZL), ceftazidime Etest (TZ) and ceftazidime/clavulanate Etest (TZ/TZL) strips were purchased from AB Biodisk, Solna, Sweden. The Etest ESBL screen is a plastic strip impregnated with ceftazidime alone (0.5-32 mg/L) at one end and both ceftazidime (0.125-8 mg/L) and clavulanate (at a constant concentration of 4 mg/L) at the other. The ceftazidime Etest strip is impregnated with ceftazidime (0.0625-256 mg/L). The ceftazidime/clavulanate Etest strip is impregnated with ceftazidime (0.0625-256 mg/L) and clavulanate (at a constant concentration of 4 mg/L).
Detection of ESBLs
Inhibitor-potentiated disc-diffusion test. Four thirdgeneration -lactams, ceftazidime, cefotaxime, ceftriaxone and aztreonam, were tested for synergy with clavulanate. This test is based on a modification of the standard discdiffusion method as described by the NCCLS. 9 MuellerHinton (MH) agar supplemented with 4 mg/L of clavulanate was prepared the day before testing with the addition of clavulanate after cooling to 50°C in a water bath. The inoculum was prepared by the direct colony suspension method to match the turbidity of a 0.5 McFarland standard. Antibiotic discs containing ceftazidime (30 g), cefotaxime (30 g), ceftriaxone (30 g) and aztreonam (30 g) were placed on 85 mm clavulanatecontaining and clavulanate-free MH agar plates using a BBL Sensi-Disc dispenser. Up to three antibiotic discs were tested per agar plate. After overnight incubation at 37°C, the diameters of the inhibition zones around the antibiotic discs were measured. Augmentation zone widths were obtained by subtracting inhibition zone diameters produced by the -lactam discs on clavulanate-free medium with those in clavulanate-containing medium. An augmentation zone width of 10 mm was considered positive for ESBL production. Each strain was tested on three separate occasions.
Etest ESBL screen. The test was performed according to the guidelines from the supplier. A greater than four-fold reduction in the ceftazidime MIC in the presence of clavulanate was taken as positive for ESBL production. 6 Double-disc synergy test. The test was performed as described by Jarlier et al. 10 Briefly, two plates were inoculated as described for the routine disc-diffusion test. Ceftazidime (30 g), cefotaxime (30 g), ceftriaxone (30 g) and aztreonam (30 g) discs were then placed 25 or 30 mm (centre to centre) away from a 20 g amoxicillin/10 g clavulanate disc before incubation. A clear extension of the edge of the inhibition zone of any of the antibiotics towards the disc containing clavulanate was interpreted as positive for ESBL production.
Kirby-Bauer disc-diffusion test.
The test was performed according to the NCCLS. 9 Diminished zones of inhibition around third-generation -lactam discs were interpreted as positive results. The -lactams and breakpoints used were: ceftazidime, 22 mm; cefotaxime, 27 mm; ceftriaxone, 25 mm; aztreonam, 27 mm. Each strain was tested on three separate occasions.
Statistical analysis
Student's t-test was used to evaluate the statistical significance of any differences in the results.
Results
Detection of ESBLs produced by control strains
The inhibitor-potentiated disc test. The ceftazidime, cefotaxime, ceftriaxone and aztreonam inhibition zone diameters were all increased in the presence of known ESBL-producing control strains and not with the ESBLnegative control strains (Table I ). The test was most sensitive with ceftazidime but most specific with cefo-taxime and ceftriaxone (Table II) . The zone augmentations with ceftazidime for one strain expressing SHV-2 and one expressing SHV-3 were <10 mm (on one of three occasions for the SHV-2 strain and on all three occasions for the SHV-3 strain). The zone augmentations with cefotaxime for these strains were 17 and 20 mm, respectively.
Etest ESBL. In the presence of clavulanate (4 mg/L), the ceftazidime MIC was reduced greater than four-fold (up to 32-fold) with 24 of the 27 ESBL-producing strains. For three strains (expressing SHV-2, -3 or -4) that initially gave false-negative results, the Etest ESBL screen test was repeated four times (Table III) . Tests with conventional Etest strips were more sensitive than Etest ESBL screening with these three strains. For non-ESBLproducing strains, the reduction in MICs ranged from nil to four-fold.
The double-disc synergy test. All except one SHV-3 strain gave positive results for ESBL production when tested by the double-disc synergy test with the discs 25 or 30 mm apart. One additional false-negative result with an SHV-2 strain occurred when ceftazidime alone was tested. For cefotaxime, ceftriaxone and aztreonam, the results with this strain were positive. For the strain producing SHV-3, a positive result was obtained when the distance between the discs was increased to 35 or 40 mm, at which point the cefotaxime and ceftriaxone zones, but not the ceftazidime and aztreonam zones, were distorted towards the clavulanate-containing disc. None of the non-ESBL producing strains gave false-positive results with the double-disc synergy test.
The Kirby-Bauer disc-diffusion test. The proportion of ESBL-producing control strains with diminished inhibition zones signifying a reduced susceptibility was 85-89% for ceftazidime, 81-85% for aztreonam, 63-67% for cefotaxime and 56-59% for ceftriaxone. Inhibition zone diameters for non-ESBL-producing strains were all larger than the NCCLS breakpoints.
Comparison of the four methods of detecting ESBLs.
All four tests showed 100% specificity for detection of ESBLs in the 45 reference and control strains. The inhibitorpotentiated disc-diffusion test was the most sensitive when two agents were used (Table IV) . Using four agents was no better than using two for any test.
Performance of methods with putative ESBLproducing E. coli and K. pneumoniae isolates from clinical specimens
The inhibitor-potentiated disc-diffusion test gave positive results ( 10 mm augmentation of the inhibition zone diameters) for all 81 clinical isolates tested. 
Discussion
Our results derived from studying reference and control strains with known susceptibility demonstrated that the inhibitor-potentiated disc-diffusion test was a highly sensitive and specific method for detecting ESBLproducing strains. Strains producing ESBLs could be clearly separated from non-producers by a breakpoint of 10 mm zone augmentation. Of the four -lactams, ceftazidime was the most sensitive indicator drug for detecting ESBLs. However, the zone augmentations with ceftazidime for one strain expressing SHV-2 and one expressing SHV-3 were <10 mm. In contrast, the zone augmentations with cefotaxime for both strains were >10 mm. The rates of hydrolysis of cefotaxime by SHV-2 and SHV-3 are >10-and 37-fold, respectively, higher than those of ceftazidime. 11, 12 In order to avoid false-negative results due to substrate specificity, our data indicated that a minimum of two agents should be tested by the inhibitorpotentiated disc-diffusion method.
For three strains expressing SHV-2, -3 and -4 which gave false-negative results with the Etest ESBL screen initially, conventional Etest strips were more sensitive. Some discrepancies with strains exhibiting lower ceftazidime MICs ( 1 mg/L) by the routine Etest and Etest ESBL screen have been found previously. 6 Further evaluation of the Etest ESBL screen is necessary to determine whether the findings reflect a problem with the design of the strips.
The present study confirmed earlier reports that the double-disc synergy test lacks sensitivity; this was only 87% when ceftazidime alone (at 25 mm disc spacing) was tested. 12 There was no loss of sensitivity when the number of drugs tested was reduced from four to two. A 30 mm disc spacing was more sensitive than a 25 mm spacing.
In this study, the routine Kirby-Bauer disc-diffusion method gave false-negative results in 11-47% of the tests for different ESBLs when testing control strains expressing known ESBLs. Katsanis et al.,
2 studying E. coli and K. pneumoniae strains transfected with various plasmids encoding TEM-3, -7, -12 and-26 and SHV-2 and -4, also found that the disc-diffusion test was insensitive for detection of ESBLs.
In testing 81 clinical isolates identified as putative ESBL-producers by the double-disc synergy test, the sensitivities of the inhibitor-potentiated disc-diffusion test and the Etest ESBL screen were identical. One advantage of the former is that three oxyimino-cephalosporin substrates, instead of only one for the latter, can be tested on one agar plate. For routine testing, the ease of screening for ESBLs by the inhibitor-potentiated disc-diffusion method could be enhanced by the development of soluble tablets that contain a suitable amount of clavulanate for addition to MH medium. A drawback of the inhibitorpotentiated disc test, which is common to all other screening methods that rely on enzyme inhibition by clavulanate (including Etest ESBL screen and double-disc synergy test), is that inhibitor-resistant groups of ESBLs might not be detected.
The accurate detection and reporting of ESBL production in clinical isolates are crucial. In human and animal infections with ESBL-producing strains, a slight increase in the MIC of oxyimino-cephalosporins has been reported to be sufficient to result in treatment failure. [13] [14] [15] [16] [17] In order to avoid compromising patient care, some have advocated that ESBL-producers be considered resistant to all extended-spectrum penicillins, cephalosporins and monobactams, even if they appear to be susceptible in vitro. 4, 9 Early detection of ESBLs will allow important infection-control decisions to be made. Routine screening of clinical isolates is therefore needed. For this purpose, the inhibitor-potentiated disc-diffusion test is more convenient than the double-disc synergy test and much less expensive than the Etest ESBL screen. The inhibitorpotentiated disc test should now be evaluated under field conditions with a wider variety of routine clinical isolates.
